BOSTON, MA – 22 May, 2017 – The Boston Biotech Meetup is featuring the work of Dr. Parmit Kumar Singh at Advances in Gene Therapy on June 6, 2017 in Boston.
RSVP for this free event at: http://meetup.com/bostonbiotech
Dr. Singh will be presenting HIV-1, cancer and splicing: the triangle.
HIV-1 based vectors are popular in gene therapy to avoid oncogene activation by gamma retrovirus based vectors in gene therapy recipients. However, there is not much information about whether HIV-1 shows preference for cancer genes. Therefore, to understand the mechanism of LEDGF/p75-dependent integration, Dr. Singh determined 1 million unique integration sites of HIV-1 in human cultured cells by pair-end Illumina sequencing.
Bioinformatic analysis of these integration sites showed that HIV-1 prefers integration into cancer genes were preferentially targeted. The result is significant as it stresses the need for further study to design a safe HIV-1 based vector for gene therapy by considering the associated risk.
Further, Dr. Singh developed new methods to do bioinformatics analysis of these one million integration sites. By this new method it was found that HIV-1 prefers integration into genes with more number of introns or highly spliced genes. Also, it showed that the preference for integration into highly spliced genes depends on LEDGF/p75.
This was a very significant result as it not only suggests the cellular role of LEDGF/p75 in splicing but also it suggests a link between the normal cellular process splicing, HIV-1 integration and cancer as it is known that misregulation of splicing causes many disease like cancer. Further studies to understand the mechanism of splicing and its role in HIV-1 integration are needed to develop a better picture.
Dr. Parmit Kumar Singh completed his PhD at Centre for Cellular and Molecular Biology (CCMB), Hyderabad, India. Dr. Singh determined the threshold size of duplicated DNA that titrates repeat induced point mutation (RIP) machinery. Moreover, He identified the first wild-isolate strain of Neurospora as a dominant suppressor of meiotic silencing. Both RIP and meiotic silencing are genome defense process in Neurospora.
During his postdoc at National Institutes of Health, he researched the integration preference of HIV-1 and his results, based on one million integration sites of HIV-1 in human cultured cells, showed that HIV-1 has preference for the highly spliced and cancer genes. The result was published in Genes and Development.
Dr. Singh has also taught at the Foundation for Advanced Education in the Science (FAES), and Uniformed Services University of the Health Sciences (USUHS), Bethesda, Maryland, USA.
Company Name: Boston Biotech Meetup
Contact Person: Maureen Gilreath
Country: United States